复发头颈癌CLR 131联合再程放疗的吞咽与唾液纵向变化
本研究纳入12例局部区域复发头颈癌患者,纵向评估CLR 131联合外照射放疗后吞咽与唾液功能变化。多数吞咽指标稳定,但5 mL布丁的喉前庭闭合时间在3个月延长,刺激性唾液流率12个月显著下降,pH 3个月降低、延伸黏度6个月升高。EAT-10与唾液pH及黏度变化强相关,提示患者报告吞咽困难对唾液改变敏感。
要点
- CLR 131联合EBRT未在早期加重客观吞咽障碍,但患者报告吞咽困难与唾液改变相关。
- 5 mL布丁的喉前庭闭合时间在3个月延长,提示需关注该时点吞咽时序。
- 刺激性唾液流率12个月显著下降,pH 3个月降低、延伸黏度6个月升高。
核心结论
- CLR 131联合EBRT在治疗后早期未加重客观吞咽障碍,但患者报告吞咽困难对唾液改变敏感。
研究设计与样本
- 纳入12例SPECT/CT显示CLR 131摄取的局部区域复发头颈癌患者。
- 于基线及治疗后3、6、12个月行视频荧光吞咽检查和刺激性唾液采集。
主要发现
- 基线时吞咽与唾液功能显著差于已发表正常数据(p < 0.001)。
- 多数吞咽指标保持稳定,但5 mL布丁的喉前庭闭合时间在3个月延长(p < 0.02)。
- 刺激性唾液流率12个月显著下降(p < 0.001),pH 3个月降低(p < 0.05),延伸黏度6个月升高(p < 0.02)。
- 基线至3个月EAT-10评分与唾液pH及黏度变化强相关(r = 0.84和-0.99)。
- 无吞咽时序指标预测DIGEST安全性或效率分级。
关键数值与推荐
- 吞咽结局包括DIGEST评分、吞咽时序指标及EAT-10患者报告吞咽困难。
- 唾液结局包括流率、pH及延伸黏度。
临床怎么用
- 对复发头颈癌再程放疗患者,可结合唾液评估与客观吞咽检查及患者报告结局监测功能毒性。
- 患者报告吞咽困难变化可能提示唾液改变,可指导针对性吞咽管理。
局限性
- 样本量仅12例,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with recurrent head and neck cancer (HNC) often present with severe, persistent dysphagia and xerostomia following prior chemoradiation. Although swallowing impairments and salivary dysfunction have been reported in this population, prior longitudinal studies have not examined changes in salivary composition or how these changes relate to swallowing physiology. PURPOSE: This study characterized longitudinal changes in swallowing and salivary function-including composition-following treatment with CLR 131, a novel tumor-selective radiotherapeutic, combined with external beam radiation therapy (EBRT). METHODS: Twelve patients with locoregionally recurrent HNC demonstrating CLR 131 uptake on SPECT/CT imaging were enrolled. Videofluoroscopic swallowing (VFS) studies and stimulated saliva collections were performed at baseline, 3, 6, and 12 months posttreatment. Outcomes included Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) scores, swallowing temporal measures, patient-reported dysphagia using Eating Assessment Tool (EAT-10), and salivary flow rate, pH, and extensional viscosity. RESULTS: At baseline, participants demonstrated significantly worse swallowing and salivary function than published normative data (p < 0.001). Most swallowing measures remained stable following treatment; however, time to laryngeal vestibule closure with 5 mL pudding was prolonged at 3 months (p < 0.02). Stimulated salivary flow rate declined significantly at 12 months (p < 0.001), while pH decreased at 3 months (p < 0.05) and extensional viscosity increased at 6 months (p < 0.02). From baseline to 3 months, EAT-10 scores were strongly associated with salivary pH and viscosity changes (r = 0.84 and -0.99, respectively). No swallowing timing measures predicted DIGEST safety or efficiency grades. CONCLUSIONS: These findings suggest that CLR 131 + EBRT did not exacerbate objective swallowing impairment in the early post-treatment period, but patient-reported dysphagia was sensitive to post-treatment salivary alterations. Integrating salivary assessments with instrumental and patient-reported outcomes may enhance detection of functional toxicity and guide targeted dysphagia management in recurrent HNC.
引用
- Wu J, Gustafson S, Hyun M, et al. Longitudinal Swallowing and Salivary Changes With CLR 131 and Re-Irradiation in Recurrent Head and Neck Cancer. Head Neck. 2026. PMID: 42141749. doi:10.1002/hed.70309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。